WO2019018119A1 - Méthodes de traitement de l'épilepsie et d'affections associées à kcnti - Google Patents

Méthodes de traitement de l'épilepsie et d'affections associées à kcnti Download PDF

Info

Publication number
WO2019018119A1
WO2019018119A1 PCT/US2018/040403 US2018040403W WO2019018119A1 WO 2019018119 A1 WO2019018119 A1 WO 2019018119A1 US 2018040403 W US2018040403 W US 2018040403W WO 2019018119 A1 WO2019018119 A1 WO 2019018119A1
Authority
WO
WIPO (PCT)
Prior art keywords
unsaturated
saturated
alkyl
alkyi
independently
Prior art date
Application number
PCT/US2018/040403
Other languages
English (en)
Inventor
Gregory R. Stewart
Chani MAHER
Bryant GAY
J. Michael ANDRESEN
Matthew Fox
David Goldstein
Steven Petrou
Slavé PETROVSKI
Original Assignee
Pairnomix, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pairnomix, Llc filed Critical Pairnomix, Llc
Publication of WO2019018119A1 publication Critical patent/WO2019018119A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de prévention, d'inhibition ou de traitement d'un ou de plusieurs symptômes associés à l'épilepsie, aux encéphalopathies ou à un dysfonctionnement cardiaque chez un mammifère. La méthode consiste à administrer au mammifère une quantité efficace d'une composition comprenant un composé de formule (I) (LXXXXIII), ou un sel pharmaceutiquement acceptable de celui-ci, ou leur combinaison quelconque.
PCT/US2018/040403 2017-07-18 2018-06-29 Méthodes de traitement de l'épilepsie et d'affections associées à kcnti WO2019018119A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762533866P 2017-07-18 2017-07-18
US62/533,866 2017-07-18
US201862648523P 2018-03-27 2018-03-27
US62/648,523 2018-03-27

Publications (1)

Publication Number Publication Date
WO2019018119A1 true WO2019018119A1 (fr) 2019-01-24

Family

ID=63042106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/040403 WO2019018119A1 (fr) 2017-07-18 2018-06-29 Méthodes de traitement de l'épilepsie et d'affections associées à kcnti

Country Status (1)

Country Link
WO (1) WO2019018119A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11236121B2 (en) 2016-08-23 2022-02-01 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN115505019A (zh) * 2022-11-07 2022-12-23 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
US11891382B2 (en) 2017-04-26 2024-02-06 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714159A (en) * 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
WO1992012715A2 (fr) * 1991-01-25 1992-08-06 The Procter & Gamble Company Emploi de loperamide et de composes apparentes dans le traitement de symptomes de maladies respiratoires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714159A (en) * 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
WO1992012715A2 (fr) * 1991-01-25 1992-08-06 The Procter & Gamble Company Emploi de loperamide et de composes apparentes dans le traitement de symptomes de maladies respiratoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIETEL T. ET AL.: "PS02-22 Quinidine: a targeted drug treatment for patients with the syndrome of malignant migrating partial seizures in infancy and KCNT1 mutation", NEUROPEDIATRICS, vol. 46, 2015, XP002784751, DOI: 10.1055/S-0035-1550734 *
FITZGERALD M.P. ET AL.: "Response to treatment in patients with KCNT1-related epilepsy(Abstract 3.368)", 1 December 2017 (2017-12-01), Annual Meeting of the American Epilepsy Society, XP002784750, Retrieved from the Internet <URL:https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/349736> [retrieved on 20110911] *
LIM CHIAO XIN ET AL: "KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects", JOURNAL OF MEDICAL GENETICS, vol. 53, no. 4, April 2016 (2016-04-01), pages 217 - 225, XP002784748 *
SATAWIRIYA M. ET AL.: "Effective treatment of quinidine in a novel KCNT1 mutation associated epileptic encephalopthy: The first case in Thailand", 219, 6 October 2017 (2017-10-06), The 13th Congress of Asian Society for Pediatric Research, XP002784749, Retrieved from the Internet <URL:http://hkjpaed.org/aspr2017/detail.asp?id=219> [retrieved on 20180911] *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912737B2 (en) 2013-04-17 2024-02-27 Sage Therpeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11236121B2 (en) 2016-08-23 2022-02-01 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
US11884696B2 (en) 2016-08-23 2024-01-30 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid
US11891382B2 (en) 2017-04-26 2024-02-06 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11603351B2 (en) 2017-07-11 2023-03-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
US11571432B2 (en) 2019-09-30 2023-02-07 Eliem Therapeutics (UK) Ltd Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US11090314B2 (en) 2019-09-30 2021-08-17 Eliem Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
CN115505019A (zh) * 2022-11-07 2022-12-23 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2019018119A1 (fr) Méthodes de traitement de l&#39;épilepsie et d&#39;affections associées à kcnti
WO2018204765A1 (fr) Méthodes de traitement de l&#39;épilepsie et d&#39;affections associées à kcnq2
WO2018064498A1 (fr) Méthodes de traitement de l&#39;épilepsie et d&#39;états neurologiques associés
KR101631342B1 (ko) 미토콘드리아 투과 전이의 억제제로서 유용한 아크릴아미도 유도체
ES2580108T3 (es) Compuestos de isoquinolina
KR100453078B1 (ko) 신규 티오우레아 화합물 및 이를 함유하는 약제학적 조성물
US8618169B2 (en) Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US6265581B1 (en) Selective β3 adrenergic agonists
WO2012009258A2 (fr) Modulateurs des récepteurs à la galanine peptidomimétiques
US6617347B1 (en) Selective β3 adrenergic agonists
CA3158057A1 (fr) Heteroarylaminosulfonamides a 5 chainons pour le traitement d&#39;etats a mediation par une activite cftr deficiente
EP0764632B1 (fr) Agonistes sélectifs bêta3-adrénergiques
Mishra et al. Discovery of potent anti-convulsant carbonic anhydrase inhibitors: design, synthesis, in vitro and in vivo appraisal
WO2014085453A2 (fr) Agonistes inverses de lxr à petites molécules
WO2006135694A2 (fr) Composes modulateurs d&#39;uii et utilisation
WO2002036588A2 (fr) Amidines inversees et methodes d&#39;utilisation pour traiter, prevenir, et inhiber la leishmaniose
BR112019020252A2 (pt) compostos úteis como inibidores de alcat 1
US9249128B2 (en) Anti-cancer serine hydrolase inhibitory carbamates
WO2019089940A1 (fr) Méthodes de traitement de l&#39;épilepsie et d&#39;états neurologiques associés
US6706754B2 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
EP3960739A1 (fr) Composé inhibiteur de la protéine grk2 et composition pharmaceutique qui le comprend
WO2018077898A1 (fr) Composés de n,n&#39;-diaryluréa, n,n&#39;-diarylthiouréa et n,n&#39;-diarylguanidino pour utilisation dans le traitement et la prévention d&#39;une maladie inflammatoire
JP2003192660A (ja) 尿素誘導体
US11884629B2 (en) N,N diethyl-N&#39;phenylpiperazine alpha 7 and alpha 9 nicotinic acetylcholine receptor agonists and antagonists
EP4205766A1 (fr) Agent prophylactique et/ou thérapeutique pour la fibrose pulmonaire idiopathique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18746795

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18746795

Country of ref document: EP

Kind code of ref document: A1